Trial
NCT05137795
Inhaled ZYESAMI (Aviptadil Acetate) for Treatment of Severe COVID-19
Phase IIIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
APR Applied Pharma Research s.a.
Collaborators
—
Condition
SARS-CoV 2
Intervention
ZYESAMI™ (aviptadil acetate)
Why stopped
Sponsor decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-14